Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Safety, Tolerability, and Efficacy Study of FLT201 in Adult Patients With Gaucher Disease Type 1 (GALILEO-1)

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label, Safety, Tolerability, and Efficacy Study of FLT201 in Adult Patients With Gaucher Disease Type 1 (GALILEO-1)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLT 201 (Primary)
  • Indications Gaucher's disease type I
  • Focus Adverse reactions; First in man
  • Acronyms GALILEO-1
  • Sponsors Spur Therapeutics

    • Most Recent Events

    • 08 Jul 2024 According to a Spur Therapeutics media release, based on efficacy and safety data company has selected a single infusion of FLT201 at a low dose of 4.5e11 vg/kg for further development in a Phase 3 trial expected to begin next year.
    • 08 Jul 2024 According to a Spur Therapeutics media release, additional data from the GALILEO-1 trial expected in the second half of 2024.
    • 08 Jul 2024 Results published in the Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top